Goldman Sachs lowers Stoke Therapeutics price target on expenses
Goldman Sachs reduced Stoke Therapeutics' (STOK) price target to $43 from $44, maintaining a Buy rating. The company reported Q3 2026 operating expenses of $88.6M, higher than estimates. Revenue was $11.25M, exceeding expectations. The Phase 3 EMPEROR trial for zorevunersen is on track for a 2027 readout. STOK trades at $26.35 with a Strong Buy consensus.
How this was made
The 30-second read
Why it matters
The analyst downgrade may trigger short‑term sell pressure, but the strong cash position and upcoming trial readout provide a longer‑term catalyst.
Market read
Primary relevance is the analyst price‑target cut following the earnings release, which may influence short‑term trading decisions for STOK.
What to watch
Potential upside from upcoming Phase 3 readout and NDA filing could offset short‑term expense concerns.
Background
Stoke Therapeutics (NASDAQ:STOK) disclosed Q3 2026 results, showing revenue beat but wider loss and higher operating costs. Goldman Sachs lowered its price target, maintaining a Buy rating.
Ticker impact
Goldman Sachs cut its price target to $43 from $44 after Stoke Therapeutics reported Q3 results with higher-than-expected expenses and a mixed earnings beat.
likely pressure as the market prices in the lower target and expense concerns
The price‑target reduction is a fresh analyst action on the same day as the earnings release, providing a clear, time‑sensitive signal.
Market effects
Biotech sector may see heightened scrutiny on expense management and trial timelines.
US biotech investors may adjust exposure to small‑cap clinical‑stage companies.
Limited; impact confined to Stoke Therapeutics and comparable micro‑cap biotech peers.
Counterpoint
Despite higher expenses, cash runway remains strong; the trial progress could justify a higher valuation.
Key entities
- AnalystGoldman Sachs
Provided the revised price target and rating.
- PartnerBiogen
Co‑developer of the EMPEROR trial for zorevunersen.

